Gerhard Zugmaier - Concepedia

Author

Gerhard Zugmaier

Also Known As

Franco Locatelli, G Zugmaier, G. ZUGMAIER, G. Zugmaier, GERHARD ZUGMAIER, Gail Roboz, Gerhard Zugmaier, V. E. Kagan, Zugmaier, G

224

Publications

15K

Citations

H-Index

Concepts

All Affiliations

Amgen (Germany)Goethe University Frankfurt Amgen (United States)Universitätsklinikum Würzburg University Hospital Schleswig-Holstein

About

Gerhard Zugmaier is an author at Amgen (Germany) specializing in medicine, cancer research, and cell biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	21	28	3.5K
2	Cell Biology	15	16	958
3	Health Sciences	8	8	303
4	Natural Sciences	1	1	53
5	Biochemistry	1	1	53

Gerhard Zugmaier

Publications

13.4K

Citations

H-Index

Page 1

	Year	Citations
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study Max S. Topp, Nicola Gökbuget, Anthony S. Stein, The Lancet Oncology Hematological MalignancyLymphoid NeoplasiaOncologyMixed-phenotype Acute LeukemiaAdult Patients	2014	1.2K
Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody Ralf C. Bargou, Eugen Leo, Gerhard Zugmaier, Science ImmunologyImmunoeditingCancer PatientsImmune Cell TherapyT Cells	2008	1.1K
Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival Max S. Topp, Peter Kufer, Nicola Gökbuget, Journal of Clinical Oncology	2011	902
Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia Nicola Gökbuget, Hervé Dombret, Massimiliano Bonifacio, Blood	2018	810
Phase II Trial of the Anti-CD19 Bispecific T Cell–Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia Max S. Topp, Nicola Gökbuget, Gerhard Zugmaier, Journal of Clinical Oncology	2014	653
Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy David T. Teachey, Susan R. Rheingold, Shannon L. Maude, Blood	2013	609
Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia Arend von Stackelberg, Franco Locatelli, Gerhard Zugmaier, Journal of Clinical Oncology	2016	597
Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines Erik W. Thompson, Soonmyoung Paik, Nils Brünner, Journal of Cellular Physiology	1992	524
Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL Max S. Topp, Nicola Gökbuget, Gerhard Zugmaier, Blood	2012	466
Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell–engaging CD19/CD3-bispecific BiTE antibody blinatumomab Matthias Klinger, Christian Brandl, Gerhard Zugmaier, Blood	2012	459

Page 1